{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-232722","form_type":"8-K","ticker":"JAGX","cik":"0001585608","company_name":"Jaguar Health, Inc.","filed_at":"2026-05-20T20:36:22+00:00","discovered_at":"2026-05-20T20:37:00.378333+00:00","generated_at":"2026-05-20T20:38:08.140070+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M","bullets":["Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.","Product revenue $1.2M, down 45% YoY; Mytesi/Canalevia-CA1 rights licensed to Future Pak in Jan 2026.","Net loss attributable to common stockholders $7.0M, improved 33% from $10.5M loss in Q1 2025.","Non-GAAP recurring EBITDA loss $5.1M, improved 48% from $9.7M loss a year ago.","Company to present crofelemer data for rare-disease intestinal failure at ESPGHAN June 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-232722","json":"https://secwatch.observer/filing/0001193125-26-232722.json","markdown":"https://secwatch.observer/filing/0001193125-26-232722.md","text":"https://secwatch.observer/filing/0001193125-26-232722.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/0001193125-26-232722-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/d143790d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-20T20:38:08.140070+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"58f14b1ab8c7fecd6b8298e8264ea247ded12c4f","claim":"Jaguar Health, Inc. reported first quarter 2026 results: revenue $20,272, net income $(7,015), EPS $(13.60).","evidence_excerpt":"per share amounts) 2026 2025 $ change % change License and grant revenue, net $ 19,068 $ 43 19,025 44244 % Product revenue, net 1,204 2,171 (967 ) -45 % Total revenue, net $ 20,272 $ 2,214 18,058 816 % Income (loss) from operations $ 10,182 $ (9,421 ) 19,602 208 % Net loss attributable to common stockholders $ (7,015 ) $ (10,464 ) 3,449 33 % Net loss per","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1585608/000119312526232722/0001193125-26-232722-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$20,272"},{"label":"Net income","value":"$(7,015)"},{"label":"EPS","value":"$(13.60)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}